BMRN BioMarin Pharmaceutical Inc. - Common Stock
Про BioMarin Pharmaceutical Inc. - Common Stock Огляд компанії з Wikipedia
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Детальніше
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.
In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016.
In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia.
In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
Джерело: Wikipedia (Англійська), CC BY-SA 4.0 · Переглянути на Wikipedia ↗
BMRN Знімок акцій Ціна, ринкова капіталізація, P/E, EPS, ROE, борг/власний капітал, діапазон 52 тижнів
BMRN Графік ціни акцій Денні OHLCV з технічними індикаторами — панування, масштабування та налаштування вашого представлення
10-річна ефективність Тренди виручки, чистого прибутку, маржі та EPS
Оцінка Співвідношення P/E, P/S, P/B, EV/EBITDA — акція дорога чи дешева?
Прибутковість Валова, операційна та чиста маржа; ROE, ROA, ROIC
Фінансове здоровʼя Борг, ліквідність, платоспроможність — міцність балансу
Зростання Зростання виручки, EPS та чистого прибутку: рік до року, 3-річний CAGR, 5-річний CAGR
Ефективність капіталу Оборотність активів, оборотність запасів, оборотність дебіторської заборгованості
BMRN Консенсус аналітиків Бичачі та ведмежі думки аналітиків, 12-місячна цільова ціна, потенціал зростання
- Активна купівля 10 30,3%
- Купівля 16 48,5%
- Утримувати 7 21,2%
- Продаж 0 0,0%
- Активний продаж 0 0,0%
12-місячна цільова ціна
25 аналітиків · 2026-08-14Історія прибутків EPS фактичний проти прогнозу, сюрприз %, коефіцієнт перевищення, дата наступного звіту про прибутки
| Період | EPS Actual | EPS прогноз | Сюрприз |
|---|---|---|---|
| 30 червня 2026 р. | $0.73 | $0.70 | 0.03% |
| 31 березня 2026 р. | $0.54 | $0.77 | -0.23% |
| 31 грудня 2025 р. | $-0.24 | $0.64 | -0.88% |
| 30 вересня 2025 р. | $-0.16 | $0.38 | -0.54% |
| 30 червня 2025 р. | $1.23 | $0.85 | 0.38% |
| 31 березня 2025 р. | $0.95 | $0.72 | 0.23% |
Порівняння з аналогами (підгалузь GICS) Ключові показники порівняно з аналогами в секторі
| Тікер | Капіталізація | P/E | Виручка рік до року | Чиста маржа | ROE | Валова маржа |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
Повні фундаментальні показники Усі показники за роками — звіт про прибутки та збитки, баланс, рух грошових коштів
Звіт про прибутки та збитки 16
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Баланс 28
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Грошовий потік 16
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Прибутковість 7
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Ліквідність та платоспроможність 3
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Ефективність 3
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Темпи зростання 9
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Оцінка (TTM) 10
| Метрика | Тенденція | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Звіт про прибутки та збитки 16
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | -383,119,000 | 192,032,000 | 191,907,000 | 190,967,000 | -379,382,000 | 190,429,000 | 190,114,000 | 188,866,000 | -375,000,000 | 188,219,000 | 187,948,000 | 186,667,000 | -369,575,000 | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | -388,203,000 | 192,032,000 | 197,091,000 | 196,474,000 | -400,206,000 | 197,147,000 | 200,505,000 | 199,262,000 | -388,939,000 | 191,173,000 | 194,998,000 | 194,363,000 | -378,968,000 | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | $-2M |
Баланс 25
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Грошовий потік 13
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Прибутковість 7
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | -0.48% | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | -1.3% | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | -0.38% | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | -0.48% | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | -0.11% | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | -0.15% | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | -0.18% |
Ліквідність та платоспроможність 5
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | 5.1 | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | 2.3 | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | -0.5 |
Ефективність 3
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | 1.3 |
Оцінка (TTM) 13
| Метрика | Тенденція | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.36B | $3.11B | · | $3.09B | $3.03B | $2.85B | · | $2.69B | $2.54B | $2.42B | · | $2.28B | $2.23B | $2.15B | · | $1.97B | |
| Net Income TTM | $360M | $501M | · | $502M | $639M | $488M | · | $342M | $292M | $236M | · | $141M | $128M | $193M | · | $105M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | $15.75B | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 31.1 | 22.1 | · | 21.1 | 16.8 | 28.2 | · | 39.7 | 54.5 | 71.0 | · | 121.2 | 129.4 | 96.3 | · | 157.0 | |
| P/S | 3.3 | 3.5 | · | 3.4 | 3.5 | 4.8 | · | 5.0 | 6.2 | 6.8 | · | 7.3 | 7.3 | 8.5 | · | 8.0 | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | 3.4 | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| P / FCF | · | 54.7 | · | · | · | 86.0 | · | · | · | 794.3 | · | · | · | -185.4 | · | · | |
| EV / EBITDA | 129.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 4.3 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3.2% | 4.5% | · | 4.8% | 6.0% | 3.5% | · | 2.5% | 1.8% | 1.4% | · | 0.83% | 0.77% | 1.0% | · | 0.64% |
Фінансова звітність Звіт про прибутки та збитки, баланс, рух грошових коштів — річні, за останні 5 років
Звіт про прибутки та збитки
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Виручка | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Операційна маржа % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Чистий прибуток | $349M | $427M | $168M | $142M | $-64M |
| Розбавлений EPS | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
Баланс
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Поточний коефіцієнт | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Коефіцієнт швидкої ліквідності | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
Грошовий потік
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Вільний грошовий потік | $725M | $487M | $63M | $55M | $209M |
Останні новини Останні заголовки, що згадують цю компанію
- Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
- Чи є BioMarin Pharmaceutical Inc. (BMRN) однією з найкращих дешевих акцій для покупки з найбільшим потенціалом зростання?
- BioMarin призначає Яна Кларка головою правління
- BioMarin Pharmaceutical (BMRN) повідомляє про позитивні результати поточних випробувань VOXZOGO
Торгові сигнали Останні сигнали купівлі/продажу із зазначенням ціни входу та коефіцієнта ризику/прибутку
Мої показники Ваш персональний список спостереження — вибрані рядки з Повних фундаментальних даних
Виберіть показники, які для вас важливі — натисніть ➕ поруч із будь-яким рядком у Повних фундаментальних даних вище.
Ваш вибір збережено і він буде застосовуватися до всіх тікерів.
Інституційні власники (13F) 616 подавачів звітності · $8.6B всього · Станом на 30 червня 2026 р.
Інституційні інвестори, які звітують про володіння цими акціями у своїй квартальній формі SEC 13F. Тільки довгі позиції; один подавець звітності може з'явитися двічі для окремих опціонних контрактів. Великі протилежні опціонні позиції (пут/кол) зазвичай відображають маркет-мейкінг або хеджування запасів, а не спрямованість переконань.
| Нові позиції | Закриті позиції | Збільшено | Зменшено | Зміна чистих акцій |
|---|---|---|---|---|
| 96 (-5 проти попереднього кв.) | 75 (+10 проти попереднього кв.) | 191 (-17 проти попереднього кв.) | 204 (+39 проти попереднього кв.) | +10.3M |
Порівняно з Q1 2026. Звіти SEC Form 13F подаються протягом 45 днів після закінчення кварталу плюс невеликий буфер для тих, хто подає із запізненням — квартали, що ще знаходяться в цьому вікні, пропускаються на користь останньої повністю звітної пари.
| Інституційний інвестор | Вартість | Акції | % від відстежуваного 13F | Тип |
|---|---|---|---|---|
| Dodge & Cox | $849 426 895 | 14 844 930 | 9,87% | Акції |
| PRIMECAP MANAGEMENT CO/CA/ | $811 962 329 | 14 190 183 | 9,44% | Акції |
| VANGUARD CAPITAL MANAGEMENT LLC | $500 310 680 | 8 743 633 | 5,82% | Акції |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494 877 355 | 8 648 678 | 5,75% | Акції |
| NORGES BANK | $469 659 128 | 8 207 954 | 5,46% | Акції |
| STATE STREET CORP | $446 370 874 | 7 800 959 | 5,19% | Акції |
| VIKING GLOBAL INVESTORS LP | $435 819 735 | 7 616 563 | 5,07% | Акції |
| Vestal Point Capital, LP | $344 750 500 | 6 025 000 | 4,01% | Акції |
| DIMENSIONAL FUND ADVISORS LP | $216 743 752 | 3 787 902 | 2,52% | Акції |
| Capital Research Global Investors | $200 521 024 | 3 504 387 | 2,33% | Акції |
| FMR LLC | $196 878 227 | 3 440 724 | 2,29% | Акції |
| Deep Track Capital, LP | $189 254 063 | 3 307 481 | 2,20% | Акції |
| GEODE CAPITAL MANAGEMENT, LLC | $180 073 856 | 3 146 120 | 2,09% | Акції |
| MILLENNIUM MANAGEMENT LLC | $118 549 312 | 2 071 816 | 1,38% | Акції |
| Assenagon Asset Management S.A. | $100 826 561 | 1 762 086 | 1,17% | Акції |
| FIRST TRUST ADVISORS LP | $91 910 897 | 1 606 273 | 1,07% | Акції |
| Jones Hill Capital LP | $81 915 580 | 1 431 590 | 0,95% | Акції |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76 264 876 | 1 332 836 | 0,89% | Акції |
| Swedbank AB | $75 232 112 | 1 314 787 | 0,87% | Акції |
| DNB Asset Management AS | $72 566 061 | 1 268 194 | 0,84% | Акції |
| Caisse de depot et placement du Quebec | $70 749 440 | 1 236 446 | 0,82% | Акції |
| VANGUARD FIDUCIARY TRUST CO | $70 030 356 | 1 223 879 | 0,81% | Акції |
| AMERIPRISE FINANCIAL INC | $65 664 916 | 1 147 544 | 0,76% | Акції |
| CITADEL ADVISORS LLC | $64 224 186 | 1 122 408 | 0,75% | Акції |
| Balyasny Asset Management L.P. | $60 344 956 | 1 054 613 | 0,70% | Акції |
| ARGA Investment Management, LP | $59 474 983 | 1 039 409 | 0,69% | Акції |
| GOLDMAN SACHS GROUP INC | $56 321 074 | 984 290 | 0,65% | Акції |
| Brandywine Global Investment Management, LLC | $56 211 687 | 945 847 | 0,65% | Акції |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54 484 884 | 952 200 | 0,63% | Опціон кол |
| MACKENZIE FINANCIAL CORP | $53 321 258 | 931 864 | 0,62% | Акції |
| FRANKLIN RESOURCES INC | $47 889 936 | 836 944 | 0,56% | Акції |
| Hudson Bay Capital Management LP | $47 206 500 | 825 000 | 0,55% | Акції |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40 949 264 | 715 646 | 0,48% | Акції |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39 869 980 | 696 784 | 0,46% | Акції |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39 311 857 | 687 030 | 0,46% | Акції |
| Palo Alto Investors LP | $39 068 500 | 682 777 | 0,45% | Акції |
| Defilade Capital Management, L.P. | $39 024 326 | 682 005 | 0,45% | Акції |
| Qube Research & Technologies Ltd | $38 270 739 | 668 835 | 0,44% | Акції |
| Eagle Health Investments LP | $35 743 961 | 624 676 | 0,42% | Акції |
| VICTORY CAPITAL MANAGEMENT INC | $34 419 661 | 601 532 | 0,40% | Акції |
| BOONE CAPITAL MANAGEMENT LLC | $33 371 791 | 583 219 | 0,39% | Акції |
| Camber Capital Management LP | $32 982 000 | 600 000 | 0,38% | Акції |
| River Road Asset Management, LLC | $31 069 888 | 542 990 | 0,36% | Акції |
| RHUMBLINE ADVISERS | $29 570 438 | 516 786 | 0,34% | Акції |
| Trails Edge Capital Partners, LP | $29 296 640 | 512 000 | 0,34% | Акції |
| BNP PARIBAS FINANCIAL MARKETS | $28 048 615 | 490 189 | 0,33% | Акції |
| Jefferies Financial Group Inc. | $26 679 283 | 466 258 | 0,31% | Акції |
| LOOMIS SAYLES & CO L P | $25 986 177 | 454 145 | 0,30% | Акції |
| RENAISSANCE TECHNOLOGIES LLC | $25 856 059 | 451 871 | 0,30% | Акції |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $25 588 784 | 447 200 | 0,30% | Акції |
| California Public Employees Retirement System | $25 124 959 | 439 094 | 0,29% | Акції |
| Rockefeller Capital Management L.P. | $24 797 775 | 433 376 | 0,29% | Акції |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24 038 122 | 420 100 | 0,28% | Опціон пут |
| SEB Asset Management AB | $23 583 178 | 412 150 | 0,27% | Акції |
| Robeco Institutional Asset Management B.V. | $23 358 064 | 408 215 | 0,27% | Акції |
| Pictet Asset Management Holding SA | $22 789 414 | 395 382 | 0,26% | Акції |
| BlackRock, Inc. | $22 697 229 | 396 666 | 0,26% | Акції |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $22 513 495 | 393 455 | 0,26% | Акції |
| PRUDENTIAL FINANCIAL INC | $22 325 585 | 390 171 | 0,26% | Акції |
| Soleus Capital Management, L.P. | $21 490 230 | 375 572 | 0,25% | Акції |
| Freestone Grove Partners LP | $20 839 181 | 364 194 | 0,24% | Акції |
| Sofinnova Investments, Inc. | $20 517 261 | 358 568 | 0,24% | Акції |
| Swiss National Bank | $20 427 540 | 357 000 | 0,24% | Акції |
| LAZARD ASSET MANAGEMENT LLC | $20 049 716 | 350 397 | 0,23% | Акції |
| BANK OF AMERICA CORP /DE/ | $19 371 831 | 338 550 | 0,23% | Акції |
| EASTERLY INVESTMENT PARTNERS LLC | $18 847 524 | 329 387 | 0,22% | Акції |
| SPHERA FUNDS MANAGEMENT LTD. | $18 799 631 | 328 550 | 0,22% | Акції |
| DIADEMA PARTNERS LP | $17 901 048 | 312 846 | 0,21% | Акції |
| SECTOR GAMMA AS | $16 875 208 | 294 918 | 0,20% | Акції |
| Rhenman & Partners Asset Management AB | $16 622 410 | 290 500 | 0,19% | Акції |
| Walleye Capital LLC | $16 492 692 | 288 233 | 0,19% | Акції |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $16 114 296 | 281 620 | 0,19% | Акції |
| ALLIANCEBERNSTEIN L.P. | $16 009 266 | 283 400 | 0,19% | Акції |
| Bridgewater Associates, LP | $15 730 407 | 274 911 | 0,18% | Акції |
| Susquehanna Portfolio Strategies, LLC | $15 653 218 | 273 562 | 0,18% | Акції |
| Redmile Group, LLC | $15 172 970 | 265 169 | 0,18% | Акції |
| Amundi | $14 864 727 | 259 782 | 0,17% | Акції |
| Eversept Partners, LP | $14 282 513 | 249 607 | 0,17% | Акції |
| Distillate Capital Partners LLC | $14 242 974 | 248 916 | 0,17% | Акції |
| RICE HALL JAMES & ASSOCIATES, LLC | $14 203 377 | 248 224 | 0,17% | Акції |
| CAPITAL FUND MANAGEMENT S.A. | $13 470 789 | 235 421 | 0,16% | Акції |
| CITADEL ADVISORS LLC | $13 189 210 | 230 500 | 0,15% | Опціон кол |
| CANADA PENSION PLAN INVESTMENT BOARD | $12 868 778 | 224 900 | 0,15% | Акції |
| M&G PLC | $12 317 472 | 216 096 | 0,14% | Акції |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12 137 385 | 214 859 | 0,14% | Акції |
| GLENMEDE TRUST CO NA | $11 782 055 | 205 908 | 0,14% | Акції |
| Retirement Systems of Alabama | $11 438 907 | 199 911 | 0,13% | Акції |
| IEQ CAPITAL, LLC | $11 328 874 | 197 988 | 0,13% | Акції |
| Mariner, LLC | $11 021 160 | 192 607 | 0,13% | Акції |
| Monaco Asset Management SAM | $10 582 095 | 184 937 | 0,12% | Акції |
| Engineers Gate Manager LP | $10 393 841 | 181 647 | 0,12% | Акції |
| VANGUARD ASSET MANAGEMENT, Ltd | $9 840 867 | 171 983 | 0,11% | Акції |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $9 713 000 | 169 746 | 0,11% | Акції |
| RAYMOND JAMES FINANCIAL INC | $9 595 050 | 167 687 | 0,11% | Акції |
| VAN ECK ASSOCIATES CORP | $9 444 504 | 165 056 | 0,11% | Акції |
| PEREGRINE CAPITAL MANAGEMENT LLC | $9 310 495 | 162 714 | 0,11% | Акції |
| CWM, LLC | $9 018 745 | 159 652 | 0,10% | Акції |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9 015 469 | 157 558 | 0,10% | Акції |
| BARCLAYS PLC | $8 865 839 | 154 943 | 0,10% | Акції |
| Legal & General Group Plc | $8 722 675 | 152 441 | 0,10% | Акції |
Інсайдери компанії 48 інсайдерів · 19 керівники · 29 директори
| Інсайдер | Роль | Остання активність | Кількість акцій у власності | Купівлі за 12 міс. | Продажі за 12 міс. | Нетто 12 міс |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17 березня 2025 р. A | 175 583 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 02 травня 2005 р. A | 14 934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 06 травня 2004 р. P | 79 285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17 березня 2025 р. A | 99 781 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 22 червня 2018 р. S | 51 070 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14 травня 2012 р. M | 41 089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13 вересня 2024 р. F | 185 074 | 0 | 0 | $0 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20 травня 2025 р. F | 30 545 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20 травня 2025 р. S | 14 173 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 17 березня 2025 р. A | 46 810 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17 березня 2025 р. A | 80 838 | 0 | 0 | $0 |
| George Eric Davis | EVP, Chief Legal Officer | 17 березня 2025 р. A | 82 915 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 02 травня 2024 р. S | 66 767 | 0 | 0 | $0 |
| Robert Baffi | EVP, Technical Operations | 22 червня 2018 р. M | 83 276 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 02 липня 2012 р. M | 59 030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 02 березня 2009 р. M | 39 621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 07 липня 2008 р. A | 12 000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 01 грудня 2005 р. M | 295 176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31 жовтня 2004 р. A | 2 740 | 0 | 0 | $0 |
| Elizabeth M Anderson | Директор | 02 червня 2026 р. A | 41 940 | 0 | 0 | $0 |
| Barbara W. Bodem | Директор | 02 червня 2026 р. A | 21 045 | 0 | 0 | $0 |
| Maykin Ho | Директор | 02 червня 2026 р. A | 35 500 | 0 | 0 | $0 |
| Mark J Enyedy | Директор | 02 червня 2026 р. A | 21 040 | 0 | 0 | $0 |
| Athena Countouriotis | Директор | 02 червня 2026 р. A | 21 040 | 0 | 0 | $0 |
| Robert J. Hombach | Директор | 02 червня 2026 р. A | 49 360 | 0 | 0 | $0 |
| Timothy P Walbert | Директор | 02 червня 2026 р. A | 17 270 | 0 | 0 | $0 |
| Ian T Clark | Директор | 02 червня 2026 р. A | 14 490 | 0 | 0 | $0 |
| Willard H Dere | Директор | 02 червня 2026 р. A | 46 440 | 0 | 0 | $0 |
| Richard A Meier | Директор | 20 травня 2025 р. A | 127 426 | 0 | 0 | $0 |
| Elaine J Heron | Директор | 03 червня 2024 р. M | 97 720 | 0 | 0 | $0 |
| David E I Pyott | Директор | 21 травня 2024 р. A | 49 750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Директор | 20 травня 2024 р. F | 473 792 | 0 | 0 | $0 |
| Dennis Slamon | Директор | 18 березня 2024 р. M | 31 299 | 0 | 0 | $0 |
| Mark J Alles | Директор | 23 травня 2023 р. A | 15 095 | 0 | 0 | $0 |
| Bryan V Lawlis | Директор | 23 травня 2023 р. A | 33 140 | 0 | 0 | $0 |
| Michael G Grey | Директор | 05 червня 2018 р. A | 34 110 | 0 | 0 | $0 |
| Alan Lewis | Директор | 05 червня 2018 р. A | 25 360 | 0 | 0 | $0 |
| Kathryn E Falberg | Директор | 15 липня 2016 р. A | 2 640 | 0 | 0 | $0 |
| William D Young | Директор | 10 червня 2015 р. A | 11 875 | 0 | 0 | $0 |
| Kenneth Bate | Директор | 10 червня 2015 р. A | 11 875 | 0 | 0 | $0 |
| Pierre Lapalme | Директор | 10 червня 2015 р. A | 31 250 | 0 | 0 | $0 |
| Joseph Klein III | Директор | 08 березня 2010 р. S | 35 000 | 0 | 0 | $0 |
| Franz L Cristiani | Директор | 14 червня 2006 р. A | — | 0 | 0 | $0 |
| Erich Sager | Директор | 24 лютого 2006 р. M | 3 309 | 0 | 0 | $0 |
| Gwynn Williams | Директор | 30 листопада 2004 р. A | 812 565 | 0 | 0 | $0 |
| John Urquhart | Директор | 28 липня 2004 р. A | — | 0 | 0 | $0 |
| BIOMARIN PHARMACEUTICAL INC | Власник 10% | 08 грудня 2012 р. J | 6 666 667 | 0 | 0 | $0 |
| Mark Wood | — | 22 травня 2013 р. M | 20 277 | 0 | 0 | $0 |
Інсайдери згідно з формами SEC 3/4/5; чистий результат = лише відкритий ринок купівлі/продажу
Активісти та власники %+ 5 4 холдинги
Інвестори, які подали Розклад SEC 13D — бенефіціарна власність понад 5% з наміром вплинути на емітента (активістські частки, кампанії в раді директорів, M&A). Кожен рядок показує останній відомий стан позиції цього подавця.
| Подавець | Подано | Частка | Статус | Мета | Подача |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 подання | 02 лютого 2015 р. | — | Первинна подача | — | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 подання | 31 липня 2009 р. | — | Первинна подача | — | SEC |
| 06 червня 2005 р. | — | Первинна подача | Кампанія в раді директорів | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 подання | 06 травня 2005 р. | — | Первинна подача | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Присутність в ETF Належить 110 ETF
Вага відображає лише прямі акціонерні володіння (N-PORT); фонди з кредитним плечем або похідними інструментами можуть мати додаткову експозицію за свопами, яка не відображається.
| Фонд | Вага | Одиниці | Станом на | Джерело |
|---|---|---|---|---|
| GNOM · Global X Funds | 4,09% | 39 792 NS | 31 травня 2026 р. | N-PORT |
| BBP · ETFis Series Trust I | 1,61% | 17 750 NS | 30 квітня 2026 р. | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,27% | 12 555 NS | 30 квітня 2026 р. | N-PORT |
| SRHQ · Elevation Series Trust | 1,14% | 40 919 NS | 30 квітня 2026 р. | N-PORT |
| RNIN · EA Series Trust | 1,12% | 31 743 NS | 30 квітня 2026 р. | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,84% | 80 485 NS | 30 квітня 2026 р. | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,83% | 133 988 NS | 30 квітня 2026 р. | N-PORT |
| LSEQ · Harbor ETF Trust | 0,69% | 1 977 NS | 30 квітня 2026 р. | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 0,64% | 18 230 NS | 31 травня 2026 р. | N-PORT |
| BIB · ProShares Trust | 0,55% | 7 110 NS | 31 травня 2026 р. | N-PORT |
| TMFX · RBB Fund, Inc. | 0,54% | 3 021 NS | 31 травня 2026 р. | N-PORT |
| ABCS · EA Series Trust | 0,48% | 948 NS | 29 травня 2026 р. | N-PORT |
| MIDE · DBX ETF Trust | 0,44% | 259 NS | 29 травня 2026 р. | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,43% | 24 857 NS | 30 квітня 2026 р. | N-PORT |
| PTMC · Pacer Funds Trust | 0,30% | 22 042 NS | 30 квітня 2026 р. | N-PORT |
| DFSV · Dimensional ETF Trust | 0,29% | 400 897 NS | 30 квітня 2026 р. | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 31 691 NS | 30 квітня 2026 р. | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,25% | 24 275 NS | 30 квітня 2026 р. | N-PORT |
| MVV · ProShares Trust | 0,24% | 6 639 NS | 31 травня 2026 р. | N-PORT |
| JIII · Janus Detroit Street Trust | 0,22% | 6 823 NS | 30 квітня 2026 р. | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,21% | 3 182 NS | 30 квітня 2026 р. | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 77 243 NS | 30 квітня 2026 р. | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,20% | 518 955 NS | 31 травня 2026 р. | N-PORT |
| UMDD · ProShares Trust | 0,17% | 927 NS | 31 травня 2026 р. | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,16% | 84 082 NS | 30 квітня 2026 р. | N-PORT |
| FNDA · SCHWAB STRATEGIC TRUST | 0,16% | 245 186 NS | 31 травня 2026 р. | N-PORT |
| DFAS · Dimensional ETF Trust | 0,14% | 361 639 NS | 30 квітня 2026 р. | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,12% | 8 557 NS | 31 травня 2026 р. | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,11% | 204 NS | 31 травня 2026 р. | N-PORT |
| PEXL · Pacer Funds Trust | 0,10% | 831 NS | 30 квітня 2026 р. | N-PORT |
| SMDX · Tidal Trust III | 0,10% | 2 255 NS | 30 квітня 2026 р. | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 6 683 NS | 30 квітня 2026 р. | N-PORT |
| DEUS · DBX ETF Trust | 0,07% | 3 563 NS | 29 травня 2026 р. | N-PORT |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,07% | 28 387 NS | 31 травня 2026 р. | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 16 069 NS | 30 квітня 2026 р. | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 4 293 NS | 30 квітня 2026 р. | N-PORT |
| DFAT · Dimensional ETF Trust | 0,06% | 145 888 NS | 30 квітня 2026 р. | N-PORT |
| FBUF · Fidelity Greenwood Street Trust | 0,05% | 177 NS | 30 квітня 2026 р. | N-PORT |
| DFSU · Dimensional ETF Trust | 0,05% | 18 028 NS | 30 квітня 2026 р. | N-PORT |
| DFAC · Dimensional ETF Trust | 0,04% | 323 150 NS | 30 квітня 2026 р. | N-PORT |
| SCHV · SCHWAB STRATEGIC TRUST | 0,04% | 97 486 NS | 31 травня 2026 р. | N-PORT |
| DCOR · Dimensional ETF Trust | 0,03% | 18 752 NS | 30 квітня 2026 р. | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,03% | 1 032 NS | 30 квітня 2026 р. | N-PORT |
| REVS · Columbia ETF Trust I | 0,03% | 1 684 NS | 30 квітня 2026 р. | N-PORT |
| GVUS · Goldman Sachs ETF Trust | 0,03% | 2 279 NS | 31 травня 2026 р. | N-PORT |
| DFUV · Dimensional ETF Trust | 0,03% | 74 757 NS | 30 квітня 2026 р. | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,03% | 2 254 NS | 31 травня 2026 р. | N-PORT |
| QARP · DBX ETF Trust | 0,03% | 341 NS | 29 травня 2026 р. | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,02% | 44 256 NS | 31 травня 2026 р. | N-PORT |
| AVLC · AMERICAN CENTURY ETF TRUST | 0,02% | 4 834 NS | 31 травня 2026 р. | N-PORT |